Antonio Giordano

Next-generation CDK inhibitors in HR+/HER2– breast cancer

Cell-cycle dysregulation is a central driver of breast cancer progression and a major therapeutic vulnerability, particularly in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR + /HER2 – ) disease. The clinical success of cyclin-dependent kinase (C...